LAWSUITS NEWS & LEGAL INFORMATION
Proton Pump Inhibitors Linked with Higher Rates of Gastric Cancer
Santa Cruz, CA: A new study on the use of proton pump inhibitors (PPI) in patients who have been treated successfully for Helicobacter pylori shows that the drugs more than double the risk for gastric cancer.
The study does have several limitations, including the fact that it is observational and was done in Hong Kong, where there are well recognized specific risks for gastric cancer in Asian patients, including diet and high rates of H. pylori.
However, according to the authors of the study, published online in Gut, on October 31, the results show a "clear dose-response and time-response" trend in PPI use and gastric cancer. Therefore, they state, the risk observed suggests the need for "caution when prescribing long-term PPIs to these patients even after successful eradication of H. pylori."
Led by Wai Keung Leung, MBChB, MD, from Queen Mary Hospital, Hong Kong, the study looked at H. pylori infection and its relationship with gastric cancer, among other outcomes. They found a greater associated risk for gastric cancer with longer duration and more frequent use of PPIs.
Despite the study’s limitations, Dr Leung and colleagues state that, to their knowledge, "this is the first study to demonstrate that long-term PPIs use, even after H. pylori eradication therapy, is still associated with an increased risk of gastric cancer. This is likely related to the profound acid suppression of PPIs that worsens atrophic gastritis, particularly in those patients with established gastric atrophy as a result of chronic H. pylori-induced inflammation."
Last updated on
FREE PROTON PUMP INHIBITOR GASTRIC CANCER LAWSUIT EVALUATION
Send your Proton Pump Inhibitor Gastric Cancer claim to a lawyer who will review your claim at NO COST or obligation.
GET LEGAL HELP NOW
GET LEGAL HELP NOW
Proton Pump Inhibitors Gastric Cancer Risk
However, according to the authors of the study, published online in Gut, on October 31, the results show a "clear dose-response and time-response" trend in PPI use and gastric cancer. Therefore, they state, the risk observed suggests the need for "caution when prescribing long-term PPIs to these patients even after successful eradication of H. pylori."
Led by Wai Keung Leung, MBChB, MD, from Queen Mary Hospital, Hong Kong, the study looked at H. pylori infection and its relationship with gastric cancer, among other outcomes. They found a greater associated risk for gastric cancer with longer duration and more frequent use of PPIs.
Despite the study’s limitations, Dr Leung and colleagues state that, to their knowledge, "this is the first study to demonstrate that long-term PPIs use, even after H. pylori eradication therapy, is still associated with an increased risk of gastric cancer. This is likely related to the profound acid suppression of PPIs that worsens atrophic gastritis, particularly in those patients with established gastric atrophy as a result of chronic H. pylori-induced inflammation."
Legal Help
If you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.Last updated on
PROTON PUMP INHIBITOR GASTRIC CANCER LEGAL ARTICLES AND INTERVIEWS
Study Further Links Proton Pump Inhibitors to Gastric Cancer and Conflicts with FDA study, Lawsuits to Follow
Georgia Plaintiff Alleges Use of Nexium Caused Chronic Kidney Disease
Childhood Asthma Risk Linked to Mother’s PPI Use during Pregnancy
May 31, 2018
Santa Clara, CA: A link between proton pump inhibitors (PPIs) and high risk of gastric cancer isn’t new, but the results of a new study conflicts with the FDA’s mandated PPI study READ MORE
Georgia Plaintiff Alleges Use of Nexium Caused Chronic Kidney Disease
March 4, 2018
Newark, NJ: Heartburn, more correctly known as acid reflux, continues to be a common complaint affecting a vast cross section of the American population. Relief is often in the form of medication - and, specifically proton pump inhibitors such as Nexium, a product of AstraZeneca. Plaintiff Shirlene Bonner began regular use of Nexium to relieve heartburn from 2003 until 2015, until a diagnosis of chronic kidney disease (CKD) found her searching for answers as to what may have triggered her CKD. Bonner alleges in her PPI lawsuit that Nexium, a proton pump inhibitor, is the root cause READ MORE
Childhood Asthma Risk Linked to Mother’s PPI Use during Pregnancy
February 5, 2018
Washington, DC: As many as 80 percent of expectant mothers suffer from heartburn or acid indigestion during pregnancy. Until recently proton pump inhibitors (PPIs), such as Nexium, Prilosec and Prevacid, were thought to be both effective for mom and safe for baby READ MORE
READ MORE Proton Pump Inhibitor Settlements and Legal News
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READER COMMENTS
Melissia Bonds
on
Patricia Letnes Jemison
on